Genital Herpes Pipeline Review 2020: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Genital Herpes - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Genital Herpes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 23 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

  • Genital Herpes - Overview
  • Genital Herpes - Therapeutics Development

Genital Herpes - Therapeutics Assessment

Genital Herpes - Companies Involved in Therapeutics Development

  • Genital Herpes - Drug Profiles

Genital Herpes - Dormant Projects

  • Genital Herpes - Discontinued Products
  • Genital Herpes - Product Development Milestones

Appendix

Companies Mentioned

  • Abivax SA
  • AiCuris GmbH & Co KG
  • Anteris Technologies Ltd
  • Astellas Pharma Inc
  • Auritec Pharmaceuticals Inc
  • Biomere LLC
  • BlueWillow Biologics Inc
  • Brandenburg Antiinfektiva GmbH
  • Johnson & Johnson
  • NanoViricides Inc
  • Profectus BioSciences Inc
  • Rational Vaccines Inc
  • Redbiotec AG
  • Sanofi
  • Shulov Innovative Science Ltd
  • SL VaxiGen Inc
  • Squarex LLC
  • Stabilitech Biopharma Ltd
  • Starpharma Holdings Ltd
  • Stealth Biologics LLC
  • Thyreos LLC
  • United BioPharma Inc
  • Vaccibody AS
  • Vaxart Inc
  • Vaxxit Srl
  • Vir Biotechnology Inc
  • Viramatix Sdn Bhd
  • Vironova Medical AB
  • X-Vax Technology Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rr356h

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900